Literature DB >> 11606042

Involvement of phosphorylation of myosin phosphatase by ROCK in trabecular meshwork and ciliary muscle contraction.

C Fukiage1, K Mizutani, Y Kawamoto, M Azuma, T R Shearer.   

Abstract

The control of smooth muscle contraction is an important factor in maintaining normal intraocular pressure. However, the specific factors causing changes in control by phosphorylation/dephosphorylation schemes in the eye are not well-defined. The purposes of this experiment were to (i) determine the localization of ROCK (Rho-associated, coiled coil-forming kinase) in monkey and rabbit eye tissues and (ii) measure phosphorylation of ROCK substrate during trabecular meshwork or ciliary muscle contraction induced by carbachol. We found that mRNAs for both ROCK I and II were expressed in most eye tissues from rabbit and monkey. Proteins for ROCK I and II were present in all eye tissues studied except lens. When trabecular meshwork or ciliary muscle were incubated with carbachol to induce contraction, phosphorylation of the myosin-binding subunit (MBS) of myosin phosphatase, a substrate for ROCK, started within 1 min and continued for at least 1 h. This phosphorylation was well correlated with contraction of trabecular meshwork or ciliary muscle. These results suggested that ROCK might regulate contraction of trabecular meshwork or ciliary muscle through phosphorylation of MBS of myosin phosphatase. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606042     DOI: 10.1006/bbrc.2001.5751

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Effect of elevated intracellular cAMP levels on actomyosin contraction in bovine trabecular meshwork cells.

Authors:  Charanya Ramachandran; Rajkumar V Patil; Najam A Sharif; Sangly P Srinivas
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-18       Impact factor: 4.799

Review 2.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

3.  Effects of Y27632 on aqueous humor outflow facility with changes in hydrodynamic pattern and morphology in human eyes.

Authors:  Chen-Yuan Charlie Yang; Ye Liu; Zhaozeng Lu; Ruiyi Ren; Haiyan Gong
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-28       Impact factor: 4.799

Review 4.  Aqueous humor outflow: dynamics and disease.

Authors:  Uttio Roy Chowdhury; Cheryl R Hann; W Daniel Stamer; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

Review 5.  Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.

Authors:  Megumi Honjo; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

Review 6.  Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.

Authors:  Ponugoti Vasantha Rao; Padmanabhan P Pattabiraman; Casey Kopczynski
Journal:  Exp Eye Res       Date:  2016-09-01       Impact factor: 3.467

7.  Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.

Authors:  Aswani Dutt Vadlapudi; Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Recent Pat Biomed Eng       Date:  2012-04-01

8.  Inhibition of RhoA signaling with increased Bves in trabecular meshwork cells.

Authors:  Patricia K Russ; Asher I Kupperman; Sai-Han Presley; Frederick R Haselton; Min S Chang
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-23       Impact factor: 4.799

9.  Novel ocular antihypertensive compounds in clinical trials.

Authors:  June Chen; Stephen A Runyan; Michael R Robinson
Journal:  Clin Ophthalmol       Date:  2011-05-20

10.  Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells.

Authors:  C Ramachandran; R V Patil; K Combrink; N A Sharif; S P Srinivas
Journal:  Mol Vis       Date:  2011-07-14       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.